Abstract: For preventing or treating keratomycosis, a medicament containing rapamycin or a salt thereof as an active ingredient is used.

Abstract: For preventing or treating keratomycosis, a medicament containing rapamycin or a salt thereof as an active ingredient is used.

Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B).

Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B).

Abstract: A method of determining the presence or the absence of a glaucoma risk by detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism, comparing the allele and/or the genotype detected with at least one of an allele and/or a genotype with a high-risk allele, wherein the presence of a glaucoma risk is determined in a case where the allele detected is the high-risk allele, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele or a heterozygote when the high-risk allele complies with a dominant genetic model, or the presence of a glaucoma risk is determined in a case where the genotype detected is a homozygote of the genotype comprising the high-risk allele when the high-risk allele complies with a recessive genetic model.

Abstract: A method for preventing or treating an optic nerve disorder, inhibiting retinal nerve cell death or recovering a neurofilament light chain expression level by administering to a patient a pharmacologically effective amount of at least one of the compound represented by the following formula (1): wherein R1 is a hydrogen atom or a lower alkyl group R2 is a hydrogen atom or a lower alkyl group; R1 and R2 may be joined to each other to form an aziridine ring, an azetidine ring, a pyrrolidine ring, a piperidine ring or an azepane ring; and R3 is a carboxyl group or an ester thereof or an amide thereof; or a salt thereof.

Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B).

Abstract: A method for treating diabetic retinopathy involving topically administering to an eye of a patient a pharmacologically effective amount of a compound represented by the following formula [II] or a salt thereof: wherein R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.

Abstract: A method for treating retinal vein occlusion involving administering to a patient a pharmacologically effective amount of a compound represented by the following formula (II) or a salt thereof: wherein R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.

Abstract: A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 514 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 514 (step B).

Abstract: An object of the present invention is to provide an angiogenesis inhibitor. The angiogenesis inhibitor according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, the ring A represents a benzene ring or a naphthalene ring; X represents a single bond, an alkylene group or —CH2COOCH2—; Y represents an oxygen atom or N(R6); R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds; R4 and R5 are the same or different and represent a hydrogen atom or an alkyl group; and R6 represents a hydrogen atom or an alkyl group.

Abstract: An object of the present invention is to provide a protective agent for a neuronal cell. The protective agent for a neuronal cell according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.

Abstract: Neuronal cell death, as modeled by removal of serum or NGF from growth medium, is characterized by many changes in gene expression. Gene expression was compared before and after withdrawal of serum or NGF. These results provide clues to underlying molecular processes occurring during neuronal and photoreceptor degeneration, and provide direction for future cell-based studies.

Abstract: A key switch in which a pair of lever members which form a cross-link member are molded out of resin materials having different shrinkage coefficients. A shaft-receiving hole is formed in the lever member molded out of the resin material having a small shrinkage coefficient, while a linking shaft is formed on the lever member molded out of the resin material having a large shrinkage coefficient. When the key switch is structured in this way, after the lever member having the shaft-receiving hole has been molded, the resin material having a large shrinkage coefficient is hardened in a die in which the shaft-receiving hole forms a portion of a cavity in order to form the other lever member. By forming the other lever member, the linking shaft is formed in a pivotally mounted state in the shaft-receiving hole. Therefore, it is no longer necessary to link the pair of lever members by a manual operation.

Abstract: Use of the compound represented by general formula (I) for remedies of and protection against eye diseases is disclosed.

Abstract: A key switch includes an actuator for rotatably engaging the upper end of one of lever members, which constitute a cross-linked member, therewith and slidably engaging the upper end of the other lever member therewith. After the cross-linked member engaged with the actuator at its upper end is mounted on a membrane switch, the bottom of a key top is retained on the actuator by a simple means a as press fitting. This simplifies a molding die for the key top and facilitates an operation of attaching the key top.

Abstract: Use of the compound represented by general formula (I) for remedies of and protection against eye diseases is disclosed. General formula (I): (wherein, R1 and R2 independently represent a lower alkyl group, R3 and R4 independently represent a hydrogen atom or a lower alkyl group).

Abstract: There will be provided a key switch in which the electrically-conductive pattern of the switch element is not oxidized, nor is patterning of the electrically-conductive pattern restricted.

Abstract: A keyboard apparatus permits easier installation of slide retaining pins to a retaining portion and prevents intrusion of dust into the keyboard apparatus from the back surface of a supporting substrate thereof. A first retaining portion has a narrow area and a wide area, and slide retaining pins are latched in the wide area. A dust-proof sheet is provided on the bottom surface of a supporting substrate to cover through holes in the supporting substrate, the through holes resulting from the formation of the first retaining portion and second retaining portions.

Abstract: A keyboard apparatus permits easier installation of slide retaining pins to a retaining portion and prevents intrusion of dust into the keyboard apparatus from the back surface of a supporting substrate thereof. A first retaining portion has a narrow area and a wide area, and slide retaining pins are latched in the wide area. A dust-proof sheet is provided on the bottom surface of a supporting substrate to cover through holes in the supporting substrate, the through holes resulting from the formation of the first retaining portion and second retaining portions.